J.W. Cole Advisors Inc. Has $1.56 Million Position in Stryker Co. (NYSE:SYK)

J.W. Cole Advisors Inc. lifted its stake in shares of Stryker Co. (NYSE:SYK) by 10.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,325 shares of the medical technology company’s stock after acquiring an additional 393 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Stryker were worth $1,557,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in SYK. Opal Wealth Advisors LLC raised its holdings in shares of Stryker by 1.6% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock valued at $654,000 after buying an additional 28 shares in the last quarter. Capital & Planning LLC raised its stake in Stryker by 3.6% in the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock worth $304,000 after buying an additional 29 shares in the last quarter. Alhambra Investment Management LLC lifted its position in Stryker by 1.5% during the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock valued at $719,000 after buying an additional 29 shares during the period. Concord Wealth Partners boosted its position in shares of Stryker by 2.2% in the 4th quarter. Concord Wealth Partners now owns 1,396 shares of the medical technology company’s stock worth $503,000 after purchasing an additional 30 shares in the last quarter. Finally, Avestar Capital LLC boosted its stake in Stryker by 1.1% in the 3rd quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock worth $1,065,000 after purchasing an additional 31 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $385.05 on Tuesday. The business has a fifty day moving average of $377.31 and a 200 day moving average of $367.19. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market capitalization of $146.79 billion, a price-to-earnings ratio of 49.62, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business earned $3.46 earnings per share. As a group, research analysts expect that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SYK. Piper Sandler restated an “overweight” rating and set a $420.00 target price (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. JMP Securities restated a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Robert W. Baird boosted their price target on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $420.68.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.